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 Abstract 
 
Background Glandular metastases (GM) (pancreas, breast, parotid, thyroid or contralateral 
adrenal) are rare in metastatic clear cell renal cell carcinoma (mccRCC).  
In a multicenter study we have assessed outcome from mccRCC with or without GM. 
Patients and methods mccRCC patients with GM or non-GM (NGN) at first presentation of 
mccRCC, treated at 9 European centers (5 French, 3 UK and 1 Belgian centers) between 
January 2004 and October 2013 were retrospectively analysed. Association between OS and 
site of metastases was assessed using the log-rank test for univariate analysis and the chi-
square test for multivariable Cox regression. 
Results 138 GM and 420 non-GM mccRCC patients were included. 37.2% GM patients were 
MSKCC favorable risk vs 18% non-GM patients, 10.7% GM patients were MSKCC poor risk 
vs 27% non-GM (p<0.0001). Median interval from metastases to treatment was 4.2 months 
(range 0-221.3 months). Median OS was 61.5 months (51.4-81.6 months) for GM and 37.4 
months (31.3-42 months) for non-GM (HR=1.7;95%CI=1.3-2.2,p<0.001). At univariate OS 
analysis, age, delay between initial diagnosis and metastases, MSKCC, bone/lung metastases 
and GM or non-GM group were significant parameters (p<0.001). At multivariate analysis, 
adjusted according to MSKCC risk group, non-GM vs GM was a strong prognostic factor 
(HR=1.4;95%CI=1.0-1.8,p=0.026); bone or liver metastases were also significant 
(HR=1.3;95%CI=1.1-1.7,p<0.02; HR=1.4;95%CI=1.1-1.7, p<0.02 respectively). Even in 
patients without bone or liver metastases, GM status was significant (HR=1.8;95%CI=1.2-
2.7,p<0.004).  
Conclusions  
This large retrospective study shows that the presence of at least one GM site at development 
of mccRCC was associated with a significantly longer OS. The presence of GM vs NGM 
disease was an independent prognostic factor for survival whether or not the poor prognostic 
factors of bone or liver metastases were present. This finding could impact on daily practice 
in which mccRCC patients with GM should receive more aggressive treatment with a 
potential for long-term survival. 
The causal mechanisms for this improved prognosis in GM mccRCC will be evaluated in 
translational studies. 
 
  
1. Introduction 
Renal cell carcinoma (RCC) accounts for 3% of adult malignancies and is the most common 
malignancy in the kidney. More than two third of patients are diagnosed with localized 
disease. About 20–30% of all patients undergoing nephrectomy for clinically localized 
disease will develop metastatic disease. Approximately 20–30% of the patients diagnosed 
with RCC already have metastatic disease at presentation (1;2). In metastatic clear cell RCC 
(mccRCC), despite new targeted therapies, prognosis remains poor and 5-year life expectancy 
is less than 20% (3). The most common sites of metastatic disease include lung (45%), bone 
(30%), lymph node (22%), liver (20%) and brain (8%) (4). Adrenal metastasis occurred in 9%, 
but few data are available concerning other glandular metastatic sites such as pancreas, breast, 
thyroid and parotid. These various metastatic sites that we considered as glandular metastases 
(GM) are infrequent site of metastasis. However kidney cancer is the most frequent tumor that 
metastasise to these sites and the evolution frequently indolent (5).  
Recent advances in understanding the molecular biology of RCC have led to the development 
of new targeted agents, which have been proven active in terms of progression-free and 
survival improvement. Some prognostic factors have been identified and combined to develop 
prognostic models. The most widely used is the Memorial Sloan–Kettering Cancer Center 
(MSKCC) score. More recently, the International Metastatic Kidney Cancer Database 
Consortium (IMDC) developed a new score (6;7). All of these scores were based on 
biological parameters, time from nephrectomy and Karnofsky performance status. In addition 
to these scores, it appears that the metastatic site may also have an impact on survival. 
Recently the International Kidney Cancer Working Group identified that bone or liver 
metastases confer a significantly poorer overall survival (OS) than other metastatic sites (8).  
Glandular metastases, particularly pancreatic and adrenal metastases are often associated with 
good survival in the literature, although the studies are based on heterogeneous patient 
populations (9;10). The aim of this study was to evaluate the impact of glandular metastases 
in mccRCC on OS in patients treated with targeted therapies, the current standard of care. 
2. Materiel and methods 
2.1. Population 
A retrospective study was performed in five centers in France, one in Belgium and three in the 
UK. Only patients who had been treated with at least one targeted therapy (anti-VEGF, TKI-
VEGFR or mTOR inhibitor) for mccRCC in each institution between January 2004 and 
October 2013 were considered for analysis. Patients treated by surgery alone, immunotherapy 
alone or without treatment for mcc-RCC were excluded from this analysis. Three of the 
centers identified mccRCC patients with or without glandular metastasis, whereas six of the 
centers only contributed to glandular metastatic RCC patients. Glandular metastatic sites were 
defined as pancreas, breast, parotid, thyroid and adrenal gland (contralateral to the primary 
tumor). Patients excluded from the study were: those with ipsilateral adrenal metastases and 
those whose metastatic disease was treated by metastasectomy alone.  
The following patient characteristics at the time of metastatic disease were collected:  
prognostic factors by MSKCC classification, sites of metastases (based on radiological and 
pathological data), local and systemic treatments for metastatic disease, survival data. Based 
on recent published data we evaluated the prognostic impact of bone and liver metastases in 
patients with glandular metastasis at diagnosis (GM) and patients without glandular 
metastases at diagnosis (NGM) (8). 
2.2. Statistical analysis 
Baseline patient and disease characteristics were summarized using descriptive analysis. 
Differences between patients with GM and NGM, were assessed using the chi-squared test for 
categorical variables and the Wilcoxon rank sum test for continuous variables. OS was 
defined as the time between the date of first diagnosis of metastases and the date of death 
from any cause. We were able to set the date of point since the diagnosis of the first 
metastases thanks to the consistency of cohort: all patients treated with anti-VEGF/mTOR 
inhibitor. Patients alive at the end of study were censored at the date of last contact. Survival 
curves for each group were estimated using the Kaplan-Meier method, and median times to 
survival for each sub-cohort were estimated with 95% confidence interval (CI). Univariate 
association between baseline characteristics and OS were evaluated with the log-rank test. 
The primary analysis model is a multivariable Cox proportional hazards regression used to 
evaluate separately the prognostic significance of specific metastatic sites (liver, bone and 
lung) and the status of the presence of glandular metastases at diagnosis while adjusting for 
differences independent predictors of poor OS (age at initial disease diagnosis <60 yrs vs >= 
60 yrs and MSKCC risk grouping). To include patients who developed glandular metastases 
later in course, a secondary landmark analysis was conducted (11). Patients still on study at 
the landmark time, 12 months after the first diagnosis of metastases, were separated into two 
group categories according to whether they have developed glandular metastases before that 
time. Patients who died or were censored before the time of landmark evaluation were 
excluded from the analysis. The prognostic significance of the presence of glandular 
metastases at the time of landmark was evaluated using a Cox regression model controlling 
for age at initial disease diagnosis and MSKCC risk grouping 
Statistical analyses were carried out using SAS version 9.4 (SAS Institute, Cary, NC, USA) 
with a nominal level of statistical significance (two-tailed) set to 0.05. 
3. Results 
 
3.1. Patient characteristics  
 
A total of 558 patients were enrolled into the study (table 1). At the time of initial diagnosis of 
metastatic disease, 138 patients had glandular metastases (GM) and 420 patients did not have 
glandular metastases (NGM). Median age was 58.0 years old [15.0-102.0], with 398 (71.3%) 
men and 160 (28.7%) women. In the GM group, the predominant glandular sites were 
contralateral adrenal gland (55.1%) and pancreatic metastases (53.6%) (Table2). The 
frequency of lung, bone and liver metastases with GM at metastatic presentation were 52.2%, 
27.5%, 14.5% compared to 74.8%, 43.1% and 25.7% for the NGM group. In the NGM group 
19.3% of patients developed one or more glandular metastases later in the course of their 
metastatic disease. Median time between initial diagnosis of kidney cancer and first diagnosis 
of metastases was significantly longer for GM compared with NGM: 22.0 months versus 4.4 
months (p<0.001).  
The majority of patients (86.2%) had a nephrectomy, only 14,5% and 13,6% didn’t undergo 
nephrectomy in GM and NGM group respectively. Of the patients who did not undergo a 
nephrectomy, 70% had primary metastatic disease and were in the poor or intermediate 
MSKCC risk group. Fuhrman grade was available for 78% of nephrectomised patients. 
Predominant Fuhrman grade of I/II was35.79% for GM vs 20.63% for NGM and grade III/IV 
79.38% for NGM vs 64.21% for GM (p=0.0024). The Fuhrman grade was not an independent 
prognostic factor for survival from MSKCC risk group (Independent test p<0.0001). Patients 
with grade Fuhrman I/II had more frequently delay between diagnosis and metastasis > 12 
months (35.5% for NGM vs 15.6% for GM) and patients with grade III-IV had more 
frequently delay < 12 months (84.4% for GM vs 64.5% for NGM   p< 0.0001). Significantly 
more patients were in the MSKCC good prognostic group in GM patients than in NGM group 
(38.3% vs 21.5%, p< 0.0001) and more patients were poor prognostic group in NGM group 
16.5% vs 6.8% in GM group. Median time from diagnosis of metastases and first anti-
angiogenic therapy was 4.14 months [0.00-160.9] for GM group and 4.11 months [0.00-
221.3] for NGM (p=0.81). There were no differences between groups on the therapeutic class 
of first anti-angiogenic treatment (Table 2). The most common treatment was Sunitinib (74%). 
3.2. Survival outcome 
 
The median follow-up for the entire cohort was 82.6 months [range 68.8-90.7] and was not 
significantly different between the two groups (p=0.54). The median OS for the entire cohort 
was 42.0 months [37.6-49.7]. The median survival for patients with GM was 61.5 months 
[51.4-81.6] and 37.4 months [31.3, 42.0] for NGM patients (Hazard Ratio (HR) [CI 95%]: 1.7 
[1.3, 2.2] p<0.001 (Figure 1).  
For patients without bone or liver metastases the median OS, in GM group (N=83) was 67.7 
months [55.4-115.6 months] and 38.7 months [30.7-50.0 months] in the NGM group 
(N=176); HR [CI 95%] 2.07 [1.42,3.02], p <0.001 (figure 2).  
3.3. Univariate and multivariate analysis of risk factors for overall survival 
 
For the entire cohort, factors that were significant in univariate analysis for longer survival 
were: younger age (< 60 years), a longer delay between diagnosis of kidney cancer and the 
first metastases, good and intermediate MSKCC score, I-II Fuhrman grade and glandular 
metastases at diagnosis (Table 3). Worse outcome was observed for patients with bone and 
lung metastases.  
On multivariate analysis adjusted for MSKCC risk group the presence of bone or liver 
metastases was significant associated with worse OS: HR [CI 95%] 1.3 [1.1-1.7] p=0.0109, 
and 1.4 (1.1-1.7) p=0.0170, respectively (Table 4). However the lung metastases were not 
associated with poorer survival on multivariate analysis (HR [CI 95%] 1.2 [0.9-1.5], 
p=0.2072). Multivariate analysis for glandular metastases at diagnosis adjusted for MSKCC 
risk group (Table 5), identified the absence of glandular metastasis irrespective of the 
metastatic location at first diagnosis, as a poor prognostic factor with an HR [CI 95%] 1.4 
[1.0-1.8] p=0.0256 for GM versus NGM. For patients without bone or liver metastases 
glandular metastases at diagnosis had a positive impact on OS HR [CI 95%] 1.8 [1.2-2.7] 
(table 6). Multivariate analysis for glandular metastases at landmark time confirmed the 
independent prognostic value of the presence of glandular status at 12-month. (HR=1.33 
[1.00-1.75], p=0.048). 
 
4.  Discussion  
The objective of this study was to determine whether the presence of glandular metastases at 
diagnosis of metastatic disease impacted on the survival of patients who received one or more 
anti-angiogenic therapies for mccRCC. RCC is known as having uncommon patterns of 
spread. Glandular metastases represent a rare site of metastases although RCC is the most 
frequent tumor to metastasize to these locations, frequently with an indolent rate of growth 
(5;12;13). In our study improvement in survival was observed for patients with GM at 
diagnosis of metastatic disease compared to NGM patients.  
The characteristics of the GM group clearly differed from NGM group, with less aggressive 
characteristics, for example: more frequent grade I/II, longer delay between kidney tumour 
and first metastases and a higher proportion of MSKCC good risk at metastatic presentation.  
The interval between nephrectomy and the occurrence of metastases correlated with survival 
and this characteristic was one of the five factors included the MSKCC risk stratification (3). 
Longer delay both between kidney cancer diagnosis and metastases as well as a good risk 
group for MSKCC were significantly more frequent in GM group. 
MSKCC risk score was used in this study because more complete information was available 
that for this population recruited since 1994, than for the now more commonly used IMDC 
risk score(6;7). Poor risk group were more frequently observed in NGM group in our study. 
Many prognostic factors have been investigated in RCC, and multiple prognostic models have 
been developed. The presence of bone or liver metastases has been evaluated and shown to be 
an independent risk factor for worse OS. The understanding of biological mechanisms 
underlying these clinical findings need to be explored (8;14) . In our study bone and liver 
metastases were more frequently observed in NGM than GM and their presence were 
significant in multivariate analysis for shorter survival. Presence of GM was associated with 
longer survival in multivariate analysis. However, median survival with or without bone or 
liver metastases was better for GM patients. The impact on the OS of glandular status at 
diagnostic of significant in multivariate analyse in patients without bone or liver metastases. 
This analysis suggests that the presence of glandular metastases at diagnosis has a positive 
impact on OS irrespective of the presence or absence of liver or bone metastases. 
Our study suffers from possible bias in patient selection and retrospective data collection. 
Although the included patients are consecutive patients, there is the probability of a selection 
bias. A limitation of this study was that the metastatic status was from chart and radiology 
review without central review. 
Moreover these results are in accordance with previous findings suggesting that glandular 
metastases, particularly to pancreas and adrenal gland, are often associated with good survival. 
(9;15). However, most reported cases come from metastasectomy series and little data is 
available for patients treated by systemic treatment (16). It is well established that patients 
with limited metastatic RCC disease can achieve an excellent survival with surgery alone (5). 
Metastasis to pancreas is a rare distant location for RCC accounting for less than 10%(14;17). 
This metastatic location is often described as indolent with a frequent long delay between 
kidney tumor and pancreas metastasis. In a review article including 15 papers with patients 
undergoing pancreatic metastasectomy had a survival median of 8.8 years, with a 5-year 
survival of 66 %, was reported (18).  
Adrenal metastases have been associated with a favorable outcome among patients with 
isolated metastases treated by surgery with an estimated 5-year survival of 60% (19). In our 
analysis we consider only contralateral adrenal metastasis as glandular metastasis. Indeed, 
some patients may have had an extended nephrectomy with adrenalectomy at the diagnosis of 
their disease. This rarely undertaken in many surgical teams now, but we wanted to avoid this 
confounding factor.  
Reoccurrence of RCC in thyroid has been described but is rare and indolent with a mean time 
from kidney cancer to metastasis around 120 months with 51% of 5-year survival after 
thyroid metastasectomy (13) . 
The association between GM localization has been highlighted in three retrospectives studies 
about thyroid metastasectomy from RCC. Thyroid metastases were associated with pancreatic 
metastases from 23 to 30% of cases (20-22). In our report, 17 patients presented a thyroid GM 
and strikingly 12 (70%) were associated with a pancreatic GM. This observation confirms a 
potential association between these two rare metastatic localizations. Iesalnieks et al. reported 
adrenal and thyroid GM association in 13% of patients and we found this association in 29% 
of patients with thyroid GM (22). These results could encourage more carefully examination 
of CT-scanner or ultrasonography to detect early thyroid metastases when pancreatic GM is 
detected during mccRCC evolution. 
The study presented here evaluated outcome of patients with glandular metastasis who were 
not surgical candidates and its strength was to compare patients all receiving anti-angiogenic 
therapy, which was not the case in most surgical reports for pancreas, thyroid or adrenal 
metastases from RCC cohorts in published papers. 
A few studies have suggested better outcomes in patients with mccRCC with GM particularly 
for patients treated by anti-angiogenic therapy. The reason for better clinical outcomes 
associated with GM has yet to be elucidated. Spread to pancreas, breast, thyroid and parotid 
gland are not routinely explored by standard staging CT scans.  A prospective systematic 
study would elucidate whether this is important, especially regarding the frequent association 
between pancreas and thyroid localizations. 
The biology behind these clinical observations needs to be explored in order to compare the 
molecular characteristics of the tumor and the metastatic site of GM and NGM patients. 
However, given the significant intratumoral heterogeneity in patients with mccRCC, the 
unique organ microenvironment of the GM may be selective for a less aggressive clinical 
phenotype. Molecular characterization of both GM and NGM in patients with mccRCC 
derived from host, tumor tissue, or plasma, may help inform the development of improved 
prognostic and predictive biomarkers. 
5. Conclusion 
 
To our knowledge this is the largest study suggesting that the presence of at least one GM at 
metastatic presentation of mccRCC, treated with a least one anti-angiogenic therapy, is 
associated with a significantly longer overall survival compared to non-GM patients. The site 
of metastatic disease can provide prognostic information and may possibly be used in guiding 
clinical decision making. The understanding of biological mechanisms to explain these 
clinical findings need to be explored. 
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Table 1: Patients characteristics at diagnosis of first metastases. 
 
 Glandular 
metastases 
Non glandular 
metastases  
p value 
 
N (%) 
 
138 
 
420 
 
 
Median age, years (range)  
 
58.0 (32-102) 
 
58.5 (15-82) 
 
0.61 
Gender Male (%) 98 (71) 300 (71.4) 0.93 
 
Nephrectomy (%) 
 
118 (85.5) 
 
363 (86.4) 
 
0.79 
Furhman grade (%) 
I/II 
III/IV 
 
34 (35.8) 
61 (64.2) 
 
66 (20.6) 
254 (79.4) 
 
0.0024 
 
 
Delay: diagnosis-
metastases, months 
(range)  
 
21.9 (0.03-
272.8) 
 
4.4 (0.03-334) 
 
<0.001 
MSKCC risk groups (%) 
- Good 
- Intermediate 
- Poor 
 
51 (38.4) 
73 (54.9) 
9 (6.8) 
 
82 (21.5) 
236 (61.9) 
63 (16.5) 
 
<0.0001 
 
 
 
 
 
 
 
 
 
Table 2: Metastatic sites at initial diagnosis of metastases. 
 
 Glandular metastases Non glandular 
metastases  
N  138 420 
Number of metastatic sites (%) 
1 
>=2 
 
4 (2.9) 
134 (97.1) 
 
23 (5.5) 
397 (94.5) 
Glandular metastatic sites (%) 
Contralateral adrenal metastases  
Pancreas 
Thyroid  
Breast 
Parotid 
 
76 (55.1) 
74 (53.6) 
17 (12.3) 
2 (1.5) 
2 (1.5) 
 
 
Non glandular metastatic sites (%) 
Lung 
Nodes 
Bone 
Ipsilateral adrenal  
Liver 
Contralateral kidney 
Brain 
Soft tissue 
Others  
 
72 (52.2) 
56 (40.6) 
38 (27.5) 
25 (18.1) 
20 (14.5) 
13 (9.4) 
11 (8.0) 
7 (5.1) 
18 (13.0) 
 
314 (74.8) 
214 (50.9) 
181 (43.1) 
35 (8.3) 
108 (25.7) 
55 (13.1) 
48 (11.4) 
44 (10.5) 
47 (11.2) 
1 non glandular metastatic site (%) 129 (93.5) 420 (100) 
Median between metastasis diagnosis and 
treatment (months) (range) 
 
4.14  [0-160.9] 
 
4.11  [0-221.3] 
Anti-angiogenic treatment (%) 
VEGFR-TKI: Sunitinib 
                    Sorafenib 
                    Pazopanib 
                    Other  
Bevacizumab  + Interferon 
mTOR inhibitor 
 
92 (67) 
24 (17) 
5 (4) 
1(0.7) 
3 (2) 
13 (9.3) 
 
323 (77) 
45 (11) 
20 (5) 
1(0.002) 
11 (0,2) 
20 (5) 
 
Table 3: Univariate analyses of survival. 
 
Characteristics N median [CI 95%] 
Hazard Ratio 
[CI 95%]  P value 
Sex     
Female 160 40.31 [30.7,49.7]  1  
Male 398 45.4 [37.8,52.0]  1.0 [0.8,1.3] 0.88 
Age     
< 60 yrs 301 52.0.98 [41.9,59.8]  1  
>= 60 yrs 257 35.6 [29.0,41.6]  1.6 [1.3,1.9]  <.001 
Furhman     
I-II 100 54.9 [48.0,68.0]  1  
III-IV 315 36.9 [30.1,42.8] 
 
0.51 [0.4,0.6] 
 
0.003 
Delay     
> 12 mo. 225 61.7 [55.4,68.0]  1  
<= 12 mo. 323 30.6 [25.6,36.8]  2.0 [1.6,2.5]  <.001 
MSKCC score     
Good 133 67.6 [57.7,97.4]  1  
Intermediate 309 39.6 [33.4,47.1]  1.9 [1.4,2.5] <.001 
Poor 72 14.01 [11.8,17.0]  5.1 [3.7,7.2]  <.001 
At diagnosis     
GM 138 61.5 [51.4,81.6]  1  
Non-GM 
Lung metastases 
No 
Yes 
420 
 
172 
386 
37.4 [31.3,42.0]  
 
 
54.6 [43.3,64.7] 
38.3 [33.2,44.7] 
1.7 [1.3,2.2]  
 
1.38 
[1.1,1.7] 
<.001 
 
 
0.006 
Bone metastases     
No 339 50.0 [41.9,57.3]  1  
Yes 219 34.9 [27.1,41.5]  1.6 [1.3,1.9]  <.001 
Liver metastases     
No 430 45.4 [37.6,52.0.]  1  
Yes 128 37.8 [24.7,47.8]  1.10 [0.9,1.4]  0.43 
 
 
 Figure 1: Kaplan-Meier for overall survival: glandular versus non glandular at 
the time of metastatic diagnosis. 
 
 
 
 
 
 
 
 
 
 
  
Median overall survival 
Glandular at metastatic diagnosis (N=138): 61.5 months [ 51.4,81.6]  
Non glandular at metastatic diagnosis (N=420): 37.4 months[31.3,42.0]  
HR [CI 95%] 1.7 [1.3-2.2] p<0.001 
 
 
 
Table 4: Multivariate analysis for survival for bone or liver metastases. Wald chi-
square test from multivariable Cox regression adjusted for the MSKCC risk group. 
 
Parameters Comparison Hazard Ratio [CI 
95%] 
p-value 
Age >=60yrs vs. <60yrs 1.3 [1.1,1.7] 0.0117 
Liver 
metastases 
Yes vs. No 1.4 [1.1,1.7] 0.0170 
MSKCC Intermediate vs. 
Good 
1.8 [1.3,2.3] <.0001 
MSKCC Poor vs. Good 4.3 [3.0,6.1] <.0001 
Bone 
metastases 
Yes vs. No 1.3 [1.1,1.7] 0.0109 
Lung 
metastases 
Yes vs. No 1.2 [0.9,1.5] 0.2072 
 
 
 
  
 Table 5: Multivariate analysis for glandular metastases at diagnosis. Wald chi-
square test from multivariable Cox regression adjusted for the MSKCC risk group. 
 
 
Parameter  Comparison Hazard Ratio [CI 95%]  p-value  
Age  >=60yrs vs. <60yrs  1.4 [1.1,1.7]  0.0059  
MSKCC  Intermediate vs. Good 1.7 [1.3,2.3]  <.0001  
MSKCC  Poor vs. Good  4.2 [3.0,6.0]  <.0001  
Glandular status at 
diagnosis  
Non-GM vs. GM 1.4 [1.0,1.8]  0.0256  
 
 
 
 
  
 Figure 2: Kaplan-Meier for overall survival: glandular metastasis versus non-
glandular metastases at the time of metastatic diagnosis for patients without 
bone or liver metastases. 
 
 
Median overall survival for patient without bone or liver metastases 
Glandular at metastatic diagnosis (N=83): 67.7 [55.4,115.6] 
Non glandular at metastatic diagnosis (N=176): 38.7 [30.7,50.0] 
HR [CI 95%] 2.1 [1.4,3.0]  p <0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6: Multivariate analysis for glandular metastases at diagnosis for patients 
without bone or liver metastases. Wald chi-square test from multivariable Cox 
regression adjusted for the MSKCC risk group. 
 
Parameters Comparison 
Hazard Ratio 
[CI 95%] p-value 
Age >=60yrs vs. <60yrs 1.7 [1.2,2.5] 0.0021 
MSKCC Intermediate vs. Good 1.4 [0.9,2.0] 0.1113 
MSKCC Poor vs. Good 2.7 [1.4,4.9] 0.0016 
Glandular status at 
diagnosis 
Non-GM vs. GM 1.8 [1.2,2.7] 0.0040 
 
 
 
 
